LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces Wells Pharma of Houston will begin shipping limited quantities of pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC), branded Niagen+, to select IV clinics including Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV in August, with additional clinics set to receive shipments soon after.

洛杉矶——（商业新闻短讯）——全球烟酰胺腺嘌呤二核苷酸（NAD+）研究权威机构ChromaDex Corp.（纳斯达克代码：CDXC）宣布，休斯顿威尔斯制药公司将开始限量装运品牌为Niagen+的药物级Niagen®（专利烟酰胺核苷氯化物或NRC），以选择IV诊所，包括Cenegenics、Clean Market/NutriDrip、Drip Hydration、EXTEN IV、Kensho Wellbeing、NAD MD、Next Health、the Medicine Room、Restore Hyper Wellness，并于8月恢复，之后不久将有更多诊所接收发货。

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute pharmaceutical-grade intravenous (IV) and injectable Niagen, which will be available in IV, shots, and intravenous-push forms exclusively at clinics, with a prescription..

U、 美国FDA注册的503B外包设施休斯顿威尔斯制药公司（Wells Pharma of Houston）将合成和分销药物级静脉注射（IV）和注射用尼亚根（Niagen），这些药物将以IV、注射和静脉推注的形式在诊所独家提供，并附有处方。。

“Science-based health clinics nationwide are eager to offer Niagen IV as a superior alternative to NAD+ IV,” said Rob Fried, CEO of ChromaDex. “We welcome this group of clinics as the first to offer Niagen IV and look forward to announcing additional availability soon.”

ChromaDex首席执行官罗伯·弗里德（RobFried）表示：“全国各地的科学诊所都渴望提供尼亚根IV作为NAD+IV的更好替代品。”。“我们欢迎这组诊所作为第一个提供尼亚根IV的诊所，并期待着尽快宣布更多的可用性。”

Niagen IV represents a significant advancement in intravenous NAD+ therapy. Compared to standard NAD+ IV treatments, Niagen IV offers superior tolerability, a 75% shorter infusion time, and a higher, faster rise in NAD+ blood levels three hours post-infusion, as measured by NAD+ dried blood spot tests (MedRxiv)..

Niagen IV代表了静脉NAD+治疗的重大进步。与标准NAD+IV治疗相比，Niagen IV具有更好的耐受性，输注时间缩短75%，输注后三小时NAD+血液水平升高更快，这是通过NAD+干血斑试验（MedRxiv）测量的。。

Increasing interest in intravenous therapies positions Niagen+ for significant growth within the intravenous hydration therapy market, valued at over $2.32 billion globally and $1.15 billion in North America in 2022 (Grand View Research). With an order already placed by Wells Pharma of Houston securing pharmaceutical-grade Niagen for clinics beyond August and hundreds more clinics in the pipeline for the rest of the year, Niagen IV is well-situated to cover the entirety of the US intravenous hydration market with ChromaDex’s new, superior product.

对静脉治疗的兴趣日益增加，使尼亚根+在静脉补液治疗市场上取得了显着增长，2022年全球价值超过23.2亿美元，北美价值超过11.5亿美元（Grand View Research）。休斯顿威尔斯制药公司（Wells Pharma of Houston）已经下了一份订单，确保8月份以后的诊所使用药物级尼亚根（Niagen），今年剩余时间还有数百家诊所正在筹备中，尼亚根IV（Niagen IV）凭借ChromaDex的新型优质产品，完全可以覆盖整个美国静脉补液市场。

Additionally, with the popularity of IV and injection procedures on the rise, we see significant opportunity to further expand into categories such as medical spas, with 11,000 locations operating in the US alone, according to the American Med Spa Association..

此外，根据美国医疗水疗协会的数据，随着静脉注射和注射程序的普及，我们看到了进一步扩展到医疗水疗等类别的重大机会，仅在美国就有11000个营业点。。

Kris Fishman, President of Wells Pharmacy Network, said, “We are thrilled to collaborate with ChromaDex on Niagen+. Through our 503B pharmacy network, we will compound this innovative product for clinics across the U.S.”

Wells Pharmacy Network总裁克里斯·菲什曼（Kris Fishman）表示：“我们很高兴与ChromaDex在Niagen+上合作。通过我们的503B药房网络，我们将为美国各地的诊所合成这种创新产品。”

Clean Market/NutriDrip, Next Health, REVIV, and Restore Hyper Wellness celebrate the launch of Niagen+:

清洁市场/NutriDrip、Next Health、Revive和Restore Hyper Wellness庆祝Niagen+的推出：

Asa Kitfield, Managing Partner at Clean Market & NutriDrip, remarked, “We are thrilled to unveil Niagen IV at Clean Market locations and The Spa by Equinox Hotels at Hudson Yards as a groundbreaking wellness solution that perfectly aligns with our commitment to enhancing health and vitality. Niagen IV offers reduced side effects and a shorter infusion time, making it more compelling than traditional NAD+ infusions.

清洁市场和NutriDrip管理合伙人Asa Kitfield表示：“我们很高兴在清洁市场地点推出Niagen IV，并在哈德逊庭院的Equinox酒店推出水疗，这是一种开创性的健康解决方案，完全符合我们增强健康和活力的承诺。Niagen IV可以减少副作用，缩短输液时间，比传统的NAD+输液更具吸引力。

This means our clients can enjoy the benefits of enhanced cellular health and energy production with greater comfort and ease. We are confident pharmaceutical grade Niagen will become a cornerstone of our injectable wellness treatments, delivering the exceptional results our clients expect.”.

这意味着我们的客户可以更加舒适和轻松地享受增强细胞健康和能量生产的好处。我们相信，药物级尼亚根将成为我们注射健康治疗的基石，为客户带来我们期望的非凡效果。”。

Darshan Shah, M.D., board-certified surgeon, founder of Next Health, and ChromaDex consultant, noted, “Niagen IV is a game changer, minimizing the unpleasant side effects of NAD+ IV and maximizing absorption. The approach ChromaDex has taken with their hero ingredient, nicotinamide riboside chloride (NRC), finally makes IV therapy for mitochondrial health a true reality.'.

董事会认证外科医生、Next Health创始人和ChromaDex顾问Darshan Shah医学博士指出，“Niagen IV是一个游戏规则的改变者，它可以最大程度地减少NAD+IV的不良副作用并最大程度地吸收。ChromaDex采用了其英雄成分烟酰胺核糖氯化物（NRC）的方法，最终使IV治疗线粒体健康成为现实。”。

Johnny Parvani, M.D., Founder and Chief Medical Officer of REVIV, added, “I am thrilled to launch Niagen IV and injections to our network of healthcare practitioners. Validated by extensive research, this groundbreaking product features ChromaDex's proprietary nicotinamide riboside chloride (NRC) technology to support cellular health.

Revive创始人兼首席医疗官Johnny Parvani医学博士补充道：“我很高兴向我们的医疗保健从业者网络推出Niagen IV和注射剂。经过广泛研究验证，这种开创性的产品具有ChromaDex专有的烟酰胺核苷氯化物（NRC）技术，可支持细胞健康。

At REVIV, we are committed to pioneering solutions that enhance human health for our customers. As a better alternative to NAD+ IV, we believe Niagen IV and injections will redefine the longevity wellness category, enabling healthcare providers to optimize patient outcomes with an innovation backed by the highest scientific and quality standards.”.

在Revive，我们致力于为客户提供改善人类健康的开创性解决方案。作为NAD+IV的更好替代品，我们相信尼亚根IV和注射剂将重新定义长寿健康类别，使医疗保健提供者能够通过最高科学和质量标准支持的创新来优化患者结果。”。

Rachele Pojednic, PhD, Director of Scientific Research at Restore Hyper Wellness, commented, 'After completing an extensive study on Niagen IV, in partnership with ChromaDex, we are impressed by its significant potential to promote longevity and enhance overall health.”

Restore Hyper Wellness的科学研究主任Rachele Pojednic博士评论道：“在与ChromaDex合作完成了对Niagen IV的广泛研究后，我们对其在促进寿命和增强整体健康方面的巨大潜力印象深刻。”

Clinics and healthcare providers interested in offering Niagen IV and injections to patients can email ChromaDex’s Vice President of Business Development, Eric Huynh, at support@niagenplus.com. Consumers can visit www.niagenplus.com to sign up for product news and updates on future clinic availability and use the store locator to find a clinic offering Niagen IV and injections near you..

有兴趣为患者提供尼亚根IV和注射的诊所和医疗保健提供者可以通过电子邮件发送给ChromaDex业务发展副总裁Eric Huynhsupport@niagenplus.com.消费者可以访问www.niagenplus.com注册产品新闻和未来诊所可用性的更新，并使用商店定位器在您附近找到一家提供尼亚根IV和注射的诊所。。

Forward-Looking Statements:

前瞻性声明：

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to rolling out limited quantities of pharmaceutical-grade Niagen (patented nicotinamide riboside chloride or NRC), branded Niagen+, to select IV clinics including Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV in August, with additional clinics set to receive shipments soon.

本新闻稿包含经修订的《1933年证券法》第27A节和经修订的《1934年证券交易法》第21E节所指的前瞻性声明，包括与推出限量的药物级尼亚根（专利烟酰胺核苷氯化物或NRC）品牌尼亚根+有关的声明，以选择IV诊所，包括Cenegenics，Clean Market/NutriDrip，Drip Hydration，EXTEN IV，Kensho Wellbeing，NAD MD，Next Health，the Medicine Room，Restore Hyper Wellness，并于8月恢复，其他诊所将很快收到发货。

Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes,' 'seeks,' 'may,' 'will,' 'should,' 'could' or the negative of such terms or other similar expressions, and include the statements regarding Niagen IV being available starting in August and nationwide thereafter; Niagen IV’s potential to reach the global intravenous hydration therapy and spa markets; the potential health benefits of Niagen IV; and the potential for Niagen IV to materially impact the overall NAD+ industry.

不描述历史事实的陈述构成前瞻性陈述，通常（但不总是）可以通过使用“期望”、“预期”、“打算”、“估计”、“计划”、“潜在”、“可能”、“可能”、“相信”、“寻求”、“可能”、“将会”、“应该”、“可能”或这些术语或其他类似表达的否定词来识别，并包括从8月开始在全国范围内提供的关于尼亚根四世的陈述；尼亚根IV在全球静脉补液疗法和水疗市场的潜力；尼亚根IV的潜在健康益处；以及尼亚根IV对整个NAD+行业产生重大影响的潜力。

These forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to the Company’s ability to secure adequate pharmaceutical grade quantities of Niagen IV in a timely manner; the Company’s ability to obtain appropriate contracts and arrangements with U.S.

这些前瞻性陈述基于公司目前的预期，并受到可能导致实际结果产生重大差异的风险和不确定性的影响，包括公司及时获得足够药物级尼亚根IV数量的能力的意外发展和相关风险；公司与美国签订适当合同和安排的能力。

FDA-registered 503B outsourcing facilities required to distribu.

美国食品和药物管理局注册了503B个外包设施，需要分发。

About ChromaDex:

关于ChromaDex：

ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+.

ChromaDex Corp.（纳斯达克：CDXC）是烟酰胺腺嘌呤二核苷酸（NAD+）的全球权威，专注于健康衰老科学。ChromaDex团队由世界著名科学家组成，与来自全球知名大学和研究机构的独立研究人员合作，以揭示NAD+的全部潜力。

A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor and quality in the dietary supplement space, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen® (patented nicotinamide riboside, or NR).

NAD+是人体每个细胞中发现的一种重要辅酶，随着年龄的增长和暴露于其他日常压力源而下降。NAD+耗竭是与年龄相关的健康和活力变化的原因。ChromaDex将其作为膳食补充剂领域科学严谨性和质量的金标准，是其经临床验证的旗舰成分Niagen®（获得专利的烟酰胺核苷或NR）背后的创新者。

Clinically proven to increase NAD+ levels, Niagen is the most efficient and superior-quality NAD+ booster helping people transform the way they age..

临床证明，尼亚根可以提高NAD+水平，是帮助人们改变衰老方式的最有效和最优质的NAD+助推器。。

Food-grade Niagen is manufactured by ChromaDex and is available in the consumer dietary supplement Tru Niagen®, the number one healthy-aging oral NAD+ supplement in the United States* (available at www.truniagen.com). Pharmaceutical-grade Niagen will be available through FDA-registered 503B outsourcing facilities and will be administered at clinics pursuant to a valid prescription (www.niagenplus.com)..

食品级尼亚根由ChromaDex生产，可在消费者膳食补充剂Tru Niagen®中获得，Tru Niagen®是美国排名第一的健康衰老口服NAD+补充剂*（可从www.truniagen.com获得）。药物级尼亚根将通过FDA注册的503B外包设施提供，并将根据有效处方（www.niagenplus.com）在诊所进行管理。。

ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, to which ChromaDex regularly publishes copies of its press releases, news, and financial information.

ChromaDex强大的专利组合保护NR和其他NAD+前体。ChromaDex在www.ChromaDex.com上维护一个网站，ChromaDex定期向其发布新闻稿、新闻和财务信息的副本。

*Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

*根据美国最大的电子商务市场（截至2023年3月1日至2024年2月29日）收入最高的膳食补充剂品牌。